Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence

Published:2017-07-24 Issue:1 Volume:19 Page:18-32
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Orkin C¹,Llibre JM²,Gallien S³,Antinori A⁴,Behrens GMN⁵⁶,Carr A⁷

Affiliation:

1. Infection and Immunity; Barts Health NHS Trust; London UK

2. University Hospital Germans Trias i Pujol; Infectious Diseases and “Fight AIDS” Foundation; Badalona Barcelona Spain

3. Immunology and Infectious Diseases; Henri Mondor Hospital; Paris Est Créteil University; Créteil France

4. HIV/AIDS Department; National Institute for Infectious Diseases “Lazzaro Spallanzani”; Rome Italy

5. Department for Clinical Immunology and Rheumatology; Hannover Medical School; Hannover Germany

6. German Center for Infection Research; St Vincent's Hospital; Sydney Australia

7. Centre for Applied Medical Research; St Vincent's Hospital; Sydney Australia

Funder

Gilead Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hiv.12534/fullpdf

Reference66 articles.

1. Impact on life expectancy of HIV-1 positive individuals of CD4 + cell count and viral load response to antiretroviral therapy;May;AIDS,2014

2. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies;Antiretroviral Therapy Cohort C;Lancet,2008

3. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals;Sighem;AIDS,2010

4. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada;Samji;PLoS ONE,2013

5. EACS EACS Guidelines Version 8.0 http://wwweacsocietyorg/guidelines/eacs-guidelines/eacs-guidelineshtml

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update;European Journal of Medicinal Chemistry;2023-12

2. Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study);British Journal of Clinical Pharmacology;2023-09-18

3. Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities;Viruses;2023-08-28

4. Utilization of Chemometric-Aided UV Spectrophotometric Methods for Concurrent Assessment of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir, and Cobicistat in Tablet Formulation;Journal of AOAC International;2023-06-08

5. Prevalence and Patterns of Adverse Drug Events Among Adult Patients with Human Immune Virus Infection on Dolutegravir-Based Antiretroviral Drug Regimens in Amhara Comprehensive Specialized Hospitals, Northwest Ethiopia: A Multicenter Retrospective Follow-Up Study;HIV/AIDS - Research and Palliative Care;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3